Clonidine/oxybutynin - Orient Pharma

Drug Profile

Clonidine/oxybutynin - Orient Pharma

Alternative Names: DL 06001; OP-014; SMT D001

Latest Information Update: 05 Feb 2016

Price : $50

At a glance

  • Originator DanioLabs
  • Developer Orient Pharma
  • Class Analgesics; Antiglaucomas; Antimigraines; Antispasmodics; Carbocyclic acids; Centrally-acting antihypertensives; Imidazolines; Mandelic acids; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Cholinergic receptor antagonists; Imidazoline receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Sialorrhoea

Most Recent Events

  • 04 Feb 2016 Preregistration for Sialorrhoea in European Union (PO) before February 2016
  • 04 Feb 2016 Preregistration for Sialorrhoea in Philippines, Canada, Japan, Hong Kong, Malaysia, India, New Zealand, South Korea and China (unspecified route) before February 2016
  • 04 Feb 2016 Preregistration for Sialorrhoea in USA (PO) before February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top